Abstract
Antisense technology provides outstanding promise for treatment of human disease, having broad applicability and high specificity. Although advances have been made in antisense oligonucleotide chemistry, leading to increased plasma and cellular stability, and decreased toxicity, considerable potential remains for the enhancement of oligonucleotide uptake for targeted delivery of oligonucleotides. One promising avenue for achieving this is via linkage of antisense oligonucleotides to peptide carriers. This review looks at the current status of developments in this area.
Keywords: antisense therapy, oligonucleotides, nuclear localisation sequences
Mini-Reviews in Medicinal Chemistry
Title: Peptide-Oligonucleotide Hybrids in Antisense Therapy
Volume: 5 Issue: 1
Author(s): Tracie L. Pierce, Anthony R. White, Geoffrey W. Tregear and Patrick M. Sexton
Affiliation:
Keywords: antisense therapy, oligonucleotides, nuclear localisation sequences
Abstract: Antisense technology provides outstanding promise for treatment of human disease, having broad applicability and high specificity. Although advances have been made in antisense oligonucleotide chemistry, leading to increased plasma and cellular stability, and decreased toxicity, considerable potential remains for the enhancement of oligonucleotide uptake for targeted delivery of oligonucleotides. One promising avenue for achieving this is via linkage of antisense oligonucleotides to peptide carriers. This review looks at the current status of developments in this area.
Export Options
About this article
Cite this article as:
Pierce L. Tracie, White R. Anthony, Tregear W. Geoffrey and Sexton M. Patrick, Peptide-Oligonucleotide Hybrids in Antisense Therapy, Mini-Reviews in Medicinal Chemistry 2005; 5 (1) . https://dx.doi.org/10.2174/1389557053402846
DOI https://dx.doi.org/10.2174/1389557053402846 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design 1,5-Diaryl-3-oxo-1,4-pentadienes: A Case for Antineoplastics with Multiple Targets
Current Medicinal Chemistry Membrane Domains and the “Lipid Raft” Concept
Current Medicinal Chemistry CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety <i>In Vitro</i> Validation of Camphene as a Potential Antiviral Agent Against Betanodavirus Causing Viral Nervous Necrosis in Barramundi
Anti-Infective Agents Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis
Mini-Reviews in Medicinal Chemistry Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design